An interventional study of Adient absorbable filter + best practice VTE prophylaxis and best practice VTE prophylaxis in Pulmonary Embolism, sponsored by Adient Medical. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Adient Medical · Not applicable, Interventional, and Prevention
The objective of the study is to evaluate the safety and efficacy of the Adient absorbable filter for the prevention of pulmonary embolism (PE: blood clot in the lungs). PE claims the lives of over 100,000 Americans each year, more than breast cancer, traffic fatalities and HIV combined.
Pharmaceutical anticoagulation (blood thinners) that reduce blood clot formation represent the standard of care for treating patients at risk for PE. However, for people who are temporarily unable to use anticoagulants, such as those who have suffered major trauma or those who are scheduled for surgical procedures, inferior vena cava (IVC) filters are used to help protect against PE. These blood filters prevent large blood clots that originate in the deep veins of the legs (deep vein thrombosis (DVT)) from reaching your lungs causing a potentially life-threatening PE.
Conventional metal IVC filters have been proven effective at reducing the incidence of PE, however, most require retrieval. If not retrieved within a timely manner (months), they can perforate the IVC, impale nearby organs with their barbed struts, and cause blood clots.
In contrast, the Adient absorbable filter traps blood clots similar to conventional metal IVC filters, but following the 8 week protection period, the filter itself breaks down into carbon dioxide and water. Hence no filter retrieval is required and complications are less likely due to the shortened indwell time. Once blood clots are trapped in the absorbable filter, the body's thrombolytic enzymes dissolve the clots within weeks while the filter itself resorbs in 6 to 8 months. The absorbable filter is braided from absorbable suture that has been proven safe over 4 decades.
The question being addressed with the randomized controlled trial portion is whether the placement of the absorbable filter in addition to current best practice PE prevention (sequential compression machines, compression stockings, and anticoagulants when indicated) significantly reduces the incidence of clinically significant PE in high risk subjects.
The absorbable filter will be indicated for the temporary prevention of PE in patients with transient high risk for venous thromboembolism (DVT and/or PE) with or without venous thromboembolic disease and as an enhancement to pharmaceutical anticoagulation and mechanical prophylaxis.
739 studies on the registry are indexed under Pulmonary Embolism; 159 are open to participants now.
This study's planned enrollment of 854 is above the median of 150 across 381 interventional studies indexed under Pulmonary Embolism.
Browse Pulmonary Embolism studies →This is the only study on the registry with Adient Medical as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Aged 18 years or older
Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study
For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure
For the prophylactic cohort, high risk VTE denoted by either:
Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma.
For the therapeutic cohort, documented VTE per the following:
Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced.
Requirement of temporary PE protection (8 weeks) based on clinical judgment
Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent.
EXCLUSION CRITERIA:
Expected high VTE risk to extend beyond 8 weeks.
Vena cava filter currently implanted
History of abdominal or pelvic radiation therapy
Previous IVC filter placement/retrieval within 6 months prior to randomization
Confirmed positive blood cultures within the last 48 hours if there is bacteremia
Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated
Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture)
Pregnant, lactating, or plans to become pregnant during investigation follow-up period
Renal insufficiency (GFR \< 60) or requiring renal replacement therapy
IVC effective diameter (D) \<16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat)
Less than 7cm from inferior-most renal vein to the iliac vein confluence
Duplication of the IVC
Any thrombus or occlusion in IVC on pre-procedural CT cavogram
Life expectancy of \< 12 months
Simultaneous participation in another investigative drug or device trial that has not reached its primary endpoint
Other co-morbid condition that, in the opinion of the Investigator, could limit the subject's ability to participate in or would affect the scientific integrity of the study
Previously enrolled in a clinical investigation of the Adient filter.
For Roll In, patient has advanced heart failure or recent (6 weeks) myocardial infarction. - - -
Advanced heart failure is defined by NYHA class IV or AHA/ACC/HFSA stage D or LVEF \< 40%. Subjects with MI diagnosed with ECG alone without MI history and symptoms are not excluded.
The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
Device: Adient absorbable filter + best practice VTE prophylaxis
The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
Device: Adient absorbable filter + best practice VTE prophylaxis
The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
Device: best practice VTE prophylaxis
Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
Primary Effectiveness Endpoint - Prophylactic Cohort: incidence of new clinically significant PE
Clinically significant PE includes asymptomatic proximal PE screened at 2 weeks, in addition to symptomatic PE through 8 weeks post index event confirmed by computed tomography (CT) angiography. Proximal PE includes thrombus (blood clots) observed in the pulmonary trunk, main pulmonary arteries, or lobar arteries.
Time frame: 2 weeks for asymptomatic proximal PE screening and through 8 weeks for symptomatic PE
Primary Composite Safety Endpoint - Prophylactic Cohort: incidence of absorbable filter deployment without complications
Potential complications include: (a) caval thrombotic occlusion within 9 months, (b) all-filter embolization within 9 months, (c) serious filter-related complications within 9 months, (d) filter placement procedural related Series Adverse Events (SAE) within the perioperative period (96 hours), (e) filter placement vascular access site SAE within the perioperative period, (f) symptomatic PE subsequent to filter deployment within 9 months.
Time frame: 96 hours to 9 months depending on the safety parameter
Primary DVT Safety Endpoint - Prophylactic Cohort: incidence of all DVT post index event
All DVT includes both symptomatic DVT and asymptomatic DVT screened at 2 weeks, 10 weeks and 9 months.
Time frame: 9 months overall duration
Primary Composite Safety and Effectiveness Endpoint - Therapeutic Cohort: composite rate of technical filter placement success without complications
Potential complications include (a) new symptomatic PE through 8 weeks, (b) filter migration (\> 2cm), (c) filter embolization, (d) caval perforation (\> 5mm), (e) symptomatic caval thrombosis, and (f) any other symptomatic filter-related complication requiring invasive intervention, or filter related death.
Time frame: 9 months
Incidence of new symptomatic PE through 8 weeks confirmed by CT angiography
Time frame: 8 weeks
Miller Score for symptomatic and asymptomatic PE
Quantification of the occlusion of the pulmonary vascular bed from a PE.
Time frame: 9 months
Incidence of caval occlusion / thrombosis confirmed by CT cavogram
Time frame: 10 weeks
Incidence of IVC caval stenosis and occlusion confirmed by CT cavogram
Time frame: 9 months
Incidence of common femoral and iliac venous thrombosis ipsilateral to filter insertion site
Detected on ultrasound.
Time frame: 2 weeks, 10 weeks, and 9 months
Incidence of DVT
Detected on ultrasound.
Time frame: 2 weeks, 10 weeks, and 9 months
Incidence of major procedure-related or device-related adverse events
Time frame: 9 months
Incidence of major bleeding
Major bleeding defined by International Society on Thrombosis and Haemostases.
Time frame: 9 months
Plan to share: No
This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.